Understanding Cannabis Use Disorder: DSM-5 Diagnostic Criteria

There is a persistent desire or unsuccessful efforts to cut down or control cannabis use.3. A great deal of time is spent in activities necessary to obtain cannabis, use cannabis, or recover from its effects.4. Recurrent cannabis use resulting in a failure to fulfill major role obligations at work, school, or home.6. Continued cannabis use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of cannabis.7. Important social, occupational, or recreational activities are given up or reduced because of cannabis use.8.

Other non-substance-related disorders

• In this study, the construct validity of DSM-5 CUD measures was examined in 392 adults with problematic substance use who currently used cannabis.
• However, major concerns regarding the combination of abuse and dependence criteria were conclusively addressed because an astonishing amount of data was available and the results were very consistent.
• The interviewers had an average of 5 years experience on census and other health-related national surveys.

The optimal treatments for most substance use disorders (SUDs) combine psychosocial and pharmacological interventions. Psychosocial-based interventions, including cognitive behavioural therapy (CBT), motivational enhancement therapy (MET) and abstinence-based contingency management combined with CBT and MET, are, therefore, the first-line treatment for adolescents and adults11–15. There is mixed support for prevention approaches such as media campaigns, and school-based, family-based and community-based programmes16–20. DSM-IV criteria were examined to identify theoretically possible subtypes of cannabis dependence based on various combinations of the criteria. Using a large, nationally representative sample of the general population, we found that cannabis dependence appears to be a disorder with a broad variety of subtypes, regardless of demographic characteristics and comorbidity with other substance use disorders. In contrast, cannabis abuse appears to be more homogenous overall, but its clinical manifestations tend to vary depending on the socio-demographic characteristics of subjects, and whether or not they suffer from comorbid disorders.

Other cannabis-induced disorders

• Using the DSM-5 CUD severity indicators, 20.7% met criteria for mild CUD, 19.1% moderate, and 27.0% severe CUD.
• DSM-IV included nicotine dependence, but experts felt that abuse criteria were inapplicable to nicotine (163, 164), so these were not included.
• Our previous work (Blanco et al., 2007) supports a similar latent structure across substances of abuse.
• However, when craving and the three abuse criteria were added, total information was increased significantly for nicotine, alcohol, cannabis, and heroin, although not for cocaine use disorders (45, 57).

Some insurance plans limit substance use disorder benefits or require specific treatment settings. Healthcare providers must recognize that F12.20 requires specific clinical documentation to support proper code assignment. The code applies when patients present with problematic cannabis use patterns combined with active intoxication symptoms at the time of evaluation. Research on the endocannabinoid system should provide insight into the aetiopathogenesis of CUD, addiction vulnerability and comorbidity with other mental disorders261. Understanding the roles of endogenous and exogenous cannabinoids may increase our knowledge of the developmental trajectories of different addictive substances if THC modifies the dopaminergic reward system to make other substances more rewarding262.

Cannabis Use Disorder DSM-5 Criteria

Attempting to cease cannabis use can provoke withdrawal symptoms, such as irritability, restlessness, sleep disturbances, and hot flashes, making the cessation process challenging for individuals grappling with CUD. Long-term cannabis use, primarily through smoking, poses potential harm to lung health. Moreover, chronic use is linked to cognitive deficits, including issues with memory and attention, affecting daily functioning and quality of life. Healthcare providers use specific CPT codes when delivering mental health services to patients with F12.20 diagnoses.

Medical professionals should document the presence of cannabis intoxication symptoms such as impaired coordination, altered perception, or cognitive changes. These symptoms must be present during the clinical encounter to justify F12.20 code assignment. With the addition of gambling disorder to the chapter, a change in the title was necessary.

None cannabis use disorder of these patients reported substance-related legal problems as their only criterion or “lost” a DSM-5 substance use disorder diagnosis without this criterion. Thus, legal problems are not a useful substance use disorder criterion, although such problems may be an important treatment focus in some settings. A cannabis withdrawal syndrome increases the difficulty of quitting and may precipitate relapse202. Data predominantly from North America estimate the prevalence of cannabis withdrawal syndrome in the general population of cannabis users at 12–17%177,203.

• Research should explore the incremental benefits of combining different treatment components and identify how best to treat common comorbid psychiatric disorders256.
• With the exception of legal problems, the criteria did not consistently indicate differential item functioning across studies.
• Your healthcare provider should review your treatment plan with you and adapt it based on your changing needs.

Some studies have found that combining CBT and MET is more effective than either treatment alone155. Augmenting CBT or MET, or combining CBT and MET with abstinence-oriented contingency management further reduces frequency of use and cannabis problem severity than either intervention alone. Most https://test-alltech-blueprint.pantheonsite.io/2023/07/13/sober-living-facilities/ studies that applied adjunctive contingency management also reported improved abstinence rates218–220, but more studies are required.

Rutgers researchers propose new way to assess medical marijuana use

The results of such work would reveal how many subtypes actually occur, and what the most common subtypes are. If a few subtypes account for a high percentage of individuals with cannabis use disorders, this would reduce concerns about the heterogeneity of the diagnostic categories. A large number of observed subtypes would suggest the need to provide information about the subtypes present in any clinical or neurobiological study, since subtype composition of the samples may help to explain the differences in results across studies. Cannabis use disorder (CUD) is an underappreciated risk of using cannabis that affects ~10% of the 193 million cannabis users worldwide. The individual and public health burdens are less than those of other forms of drug use, but CUD accounts for Alcohol Use Disorder a substantial proportion of persons seeking treatment for drug use disorders owing to the high global prevalence of cannabis use.